BRANDI FOREE: Open Payments
NPI 1598283012 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$976 in 45 payments from 11 companies in 2025. Trend: 2023 $991 · 2024 $1,374 · 2025 $976
Food & beverage: $976
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $247 |
| AstraZeneca Pharmaceuticals LP | 2 | $141 |
| Indivior Inc. | 7 | $109 |
| Orexo US, Inc. | 6 | $103 |
| Abbott Laboratories | 4 | $92 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $85 |
| Otsuka America Pharmaceutical, Inc. | 3 | $77 |
| Gilead Sciences, Inc. | 3 | $68 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Medtronic, Inc. | 1 | $18 |
Products named: MAVYRET, WAINUA, SUBLOCADE, Zubsolv, CAPLYTA, REXULTI, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, VRAYLAR.
Industry payments across IN — which companies pay providers there.
